Strides Pharma Science Ltd. has announced its consolidated financial results for the quarter (Q1FY25).

Arun Kumar, Founder and Executive Chairperson, and Badree Komandur, MD and Group CEO, commented on the performance and said, “Our emphasis on profitability, efficiency and growth has led to a strong performance across markets, allowing us to deliver superior returns ahead of the projected timelines for our FY25 outlook. The company achieved critical thresholds of 20 percent EBITDA margin, INR 683 million of reported PAT and 2.3x Debt/EBITDA ratio. We are confident of sustaining the momentum with continuous improvement in the quality of business. The company has increased its focus on digitization, automation, and ESG for better compliance and business outcomes.”

The company reported revenues of INR 10,875 million for Q1FY25, a significant increase of 16.7 percent compared to INR 9,320 million in Q1FY24. On a quarter-on-quarter basis, revenues grew by 2.8 percent from INR 10,583 million in Q4FY24.

Strides Pharma achieved a gross margin of INR 6,671 million in Q1FY25, up 21.9 percent from INR 5,470 million in Q1FY24. This quarter also saw a 3.9 percent rise from the INR 6,421 million reported in Q4FY24. The gross margin percentage stood at 61.3 percent, an increase of 264 basis points (bps) year-on-year from 58.7 percent, and a rise of 67 bps quarter-on-quarter from 60.7 percent.

Earnings before interest, taxes, depreciation, and amortization (EBITDA) for Q1FY25 amounted to INR 2,170 million, reflecting a 28.7 percent growth from INR 1,686 million in Q1FY24. On a quarterly basis, EBITDA grew by 6.4 percent from INR 2,040 million in Q4FY24. The EBITDA margin was 20.0 percent, an improvement of 187 bps year-on-year from 18.1 percent, and 68 bps quarter-on-quarter from 19.3 percent.

The adjusted profit after tax (PAT) for Q1FY25 was INR 839 million, a substantial increase compared to INR 295 million in Q1FY24 and INR 670 million in Q4FY24. The reported PAT for Q1FY25 was INR 683 million, significantly improving from a loss of INR 94 million in Q1FY24 and an increase from INR 104 million in Q4FY24.